Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects

S. Caprio, G. Gerety, W. V. Tamborlane, T. Jones, M. Diamond, R. Jacob, R. S. Sherwin

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To examine the impact of opiate blockade on glucose counterregulation we performed two hypoglycemic insulin clamp studies with and without naloxone in healthy subjects and well-controlled insulin-dependent (IDDM) patients with defective glucose counterregulation. During both studies plasma glucose fell to 55-60 mg/dl and was then maintained at that level using a variable glucose infusion. In normal subjects, naloxone increased glucose production, thereby reducing the exogenous glucose dose needed to maintain the hypoglycemic plateau. Epinephrine and cortisol responses to hypoglycemia were increased during naloxone plus insulin compared with insulin alone; glucagon responses were unaffected. IDDM patients with suppressed hepatic and hormonal responses to insulin-induced hypoglycemia also demonstrated greater stimulation of glucose production as well as epinephrine, growth hormone, and cortisol release during the naloxone study. In the absence of hypoglycemia, naloxone did not significantly affect glucose production or glucoregulatory hormones. We conclude that opiate blockade augments glucoregulatory responses to insulin-induced hypoglycemia, even in IDDM patients with preexisting defects in glucose counterregulation. This effect is at least in part due to enhanced counterregulatory hormone release during hypoglycemia. Endogenous opiates may modulate hormonal responses during hypoglycemia; their blockade could provide a means of ameliorating defective counterregulation in IDDM patients.

Original languageEnglish (US)
Pages (from-to)E852-E858
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume260
Issue number6 23/6
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Opiate Alkaloids
Hypoglycemic Agents
Insulin
Hypoglycemia
Glucose
Naloxone
Type 1 Diabetes Mellitus
Epinephrine
Hydrocortisone
Hormones
Opioid Peptides
Glucagon
Growth Hormone
Healthy Volunteers

Keywords

  • Epinephrine
  • Hepatic glucose production
  • Hypoglycemia
  • Naloxone

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Physiology (medical)

Cite this

Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects. / Caprio, S.; Gerety, G.; Tamborlane, W. V.; Jones, T.; Diamond, M.; Jacob, R.; Sherwin, R. S.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 260, No. 6 23/6, 01.01.1991, p. E852-E858.

Research output: Contribution to journalArticle

Caprio, S, Gerety, G, Tamborlane, WV, Jones, T, Diamond, M, Jacob, R & Sherwin, RS 1991, 'Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects', American Journal of Physiology - Endocrinology and Metabolism, vol. 260, no. 6 23/6, pp. E852-E858.
Caprio, S. ; Gerety, G. ; Tamborlane, W. V. ; Jones, T. ; Diamond, M. ; Jacob, R. ; Sherwin, R. S. / Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects. In: American Journal of Physiology - Endocrinology and Metabolism. 1991 ; Vol. 260, No. 6 23/6. pp. E852-E858.
@article{67955a20d56a4eff89a3d7caf4f15125,
title = "Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects",
abstract = "To examine the impact of opiate blockade on glucose counterregulation we performed two hypoglycemic insulin clamp studies with and without naloxone in healthy subjects and well-controlled insulin-dependent (IDDM) patients with defective glucose counterregulation. During both studies plasma glucose fell to 55-60 mg/dl and was then maintained at that level using a variable glucose infusion. In normal subjects, naloxone increased glucose production, thereby reducing the exogenous glucose dose needed to maintain the hypoglycemic plateau. Epinephrine and cortisol responses to hypoglycemia were increased during naloxone plus insulin compared with insulin alone; glucagon responses were unaffected. IDDM patients with suppressed hepatic and hormonal responses to insulin-induced hypoglycemia also demonstrated greater stimulation of glucose production as well as epinephrine, growth hormone, and cortisol release during the naloxone study. In the absence of hypoglycemia, naloxone did not significantly affect glucose production or glucoregulatory hormones. We conclude that opiate blockade augments glucoregulatory responses to insulin-induced hypoglycemia, even in IDDM patients with preexisting defects in glucose counterregulation. This effect is at least in part due to enhanced counterregulatory hormone release during hypoglycemia. Endogenous opiates may modulate hormonal responses during hypoglycemia; their blockade could provide a means of ameliorating defective counterregulation in IDDM patients.",
keywords = "Epinephrine, Hepatic glucose production, Hypoglycemia, Naloxone",
author = "S. Caprio and G. Gerety and Tamborlane, {W. V.} and T. Jones and M. Diamond and R. Jacob and Sherwin, {R. S.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "260",
pages = "E852--E858",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "6 23/6",

}

TY - JOUR

T1 - Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects

AU - Caprio, S.

AU - Gerety, G.

AU - Tamborlane, W. V.

AU - Jones, T.

AU - Diamond, M.

AU - Jacob, R.

AU - Sherwin, R. S.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To examine the impact of opiate blockade on glucose counterregulation we performed two hypoglycemic insulin clamp studies with and without naloxone in healthy subjects and well-controlled insulin-dependent (IDDM) patients with defective glucose counterregulation. During both studies plasma glucose fell to 55-60 mg/dl and was then maintained at that level using a variable glucose infusion. In normal subjects, naloxone increased glucose production, thereby reducing the exogenous glucose dose needed to maintain the hypoglycemic plateau. Epinephrine and cortisol responses to hypoglycemia were increased during naloxone plus insulin compared with insulin alone; glucagon responses were unaffected. IDDM patients with suppressed hepatic and hormonal responses to insulin-induced hypoglycemia also demonstrated greater stimulation of glucose production as well as epinephrine, growth hormone, and cortisol release during the naloxone study. In the absence of hypoglycemia, naloxone did not significantly affect glucose production or glucoregulatory hormones. We conclude that opiate blockade augments glucoregulatory responses to insulin-induced hypoglycemia, even in IDDM patients with preexisting defects in glucose counterregulation. This effect is at least in part due to enhanced counterregulatory hormone release during hypoglycemia. Endogenous opiates may modulate hormonal responses during hypoglycemia; their blockade could provide a means of ameliorating defective counterregulation in IDDM patients.

AB - To examine the impact of opiate blockade on glucose counterregulation we performed two hypoglycemic insulin clamp studies with and without naloxone in healthy subjects and well-controlled insulin-dependent (IDDM) patients with defective glucose counterregulation. During both studies plasma glucose fell to 55-60 mg/dl and was then maintained at that level using a variable glucose infusion. In normal subjects, naloxone increased glucose production, thereby reducing the exogenous glucose dose needed to maintain the hypoglycemic plateau. Epinephrine and cortisol responses to hypoglycemia were increased during naloxone plus insulin compared with insulin alone; glucagon responses were unaffected. IDDM patients with suppressed hepatic and hormonal responses to insulin-induced hypoglycemia also demonstrated greater stimulation of glucose production as well as epinephrine, growth hormone, and cortisol release during the naloxone study. In the absence of hypoglycemia, naloxone did not significantly affect glucose production or glucoregulatory hormones. We conclude that opiate blockade augments glucoregulatory responses to insulin-induced hypoglycemia, even in IDDM patients with preexisting defects in glucose counterregulation. This effect is at least in part due to enhanced counterregulatory hormone release during hypoglycemia. Endogenous opiates may modulate hormonal responses during hypoglycemia; their blockade could provide a means of ameliorating defective counterregulation in IDDM patients.

KW - Epinephrine

KW - Hepatic glucose production

KW - Hypoglycemia

KW - Naloxone

UR - http://www.scopus.com/inward/record.url?scp=0025745461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025745461&partnerID=8YFLogxK

M3 - Article

C2 - 2058661

AN - SCOPUS:0025745461

VL - 260

SP - E852-E858

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 6 23/6

ER -